Rep. Folmer requires added procedure during NHL treatment

Pennsylvania State Senator Mike Folmer, who recently announced he had been diagnosed with follicular non-Hodgkin's lymphoma, is currently undergoing anti-cancer treatment but will require an added procedure, according to Rep. Folmer.

Folmer, who represents the state's 48th Senate District, has undergone one round of chemotherapy and is scheduled for his second of six total on 19 March.

However, Folmer has learned that he will require a procedure known as a pericardial window, which is a procedure that drains accumulated fluid in his chest region (pericardium). It is this accumulation that partly led to his diagnosis last year. While he has had the fluid drained before, this is said to be a more permanent solution to the problem.

He is expected to be in the hospital for a couple of days for the procedure.

Source: WFMZ

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap